Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Kaduna, Nigeria.
Department of Pharmacognosy and Drug Development, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Kaduna, Nigeria.
Acta Parasitol. 2022 Mar;67(1):120-129. doi: 10.1007/s11686-021-00437-w. Epub 2021 Jun 22.
Trypanosomiasis is a neglected disease of humans and livestock caused by single-celled flagellated haemo-protozoan parasites belonging to the genus Trypanosoma.
Widespread resistance to trypanocidal drugs creates urgent need for new, more effective drugs with potential to inhibit important trypanosome molecular targets.
Nine column chromatographic, partially purified leaf fractions of Azadirachta indica (AIF) were subjected to trypanosome alternative oxidase (TAO) inhibition assay using ubiquinol oxidase assay. The potent TAO inhibitors were evaluated for trypanocidal activities against T. congolense in rat model using in vitro, ex vivo, and in vivo assays. Complete cessation or reduction in parasite motility was scored from 0 (no parasite) to 6 (greater than or equal to 6 × 10 trypanosomes/milliliter of blood), and was used to evaluate the efficacy of in vitro treatments.
Only AIF1, AIF2, and AIF5 significantly inhibited TAO. AIF1 and AIF5 produced significant, dose-dependent suppression of parasite motility reaching score zero within 1 h with EC of 0.005 and 0.004 µg/µL, respectively, while trypanosome-laden blood was still at score six with an EC of 44,086 µg/µL. Mice inoculated with the concentrations at scores 0 and 1 (1-2 moribund parasites) at the end of the experiment did not develop parasitaemia. The two fractions significantly (p < 0.05) lowered parasite burden, with the AIF5 exhibiting highest in vivo trypanocidal effects. Packed cell volume was significantly higher in AIF1 (p < 0.05) and AIF5 (p < 0.001) groups compared to DMSO-treated group. Only AIF5 significantly (p < 0.05) lowered malondialdehyde.
AIF1 and AIF5 offer prospects for the discovery of TAO inhibitor(s).
锥虫病是一种由单细胞鞭毛原生动物寄生虫属锥虫引起的人类和牲畜的被忽视疾病。
由于广泛存在对抗锥虫药物的耐药性,因此迫切需要新的、更有效的药物,这些药物有可能抑制重要的锥虫分子靶标。
采用 ubiquinol 氧化酶测定法,对印楝(AIF)的 9 个柱层析、部分纯化的叶部分进行锥虫替代氧化酶(TAO)抑制试验。对潜在的 TAO 抑制剂进行了评价,以评估其在大鼠模型中的抗 T. congolense 活性,采用体外、离体和体内试验。根据寄生虫运动的完全停止或减少,从 0(无寄生虫)到 6(大于或等于 6×10 个锥虫/毫升血液)进行评分,并用于评估体外治疗的疗效。
只有 AIF1、AIF2 和 AIF5 显著抑制了 TAO。AIF1 和 AIF5 显著抑制了寄生虫的运动,在 1 小时内达到 0 分,EC 分别为 0.005 和 0.004μg/μL,而载有锥虫的血液仍为 6 分,EC 为 44086μg/μL。在实验结束时,接种浓度为 0 分和 1 分(1-2 只濒死寄生虫)的小鼠没有发生寄生虫血症。这两种分数显著(p<0.05)降低了寄生虫负荷,其中 AIF5 表现出最高的体内抗锥虫作用。与 DMSO 处理组相比,AIF1(p<0.05)和 AIF5(p<0.001)组的红细胞压积明显升高。只有 AIF5 显著(p<0.05)降低了丙二醛。
AIF1 和 AIF5 为发现 TAO 抑制剂提供了前景。